Announcement of Sansure Biotech Inc. regarding the proposal of the actual controller and director to distribute interim dividends, cancel some repurchased shares and implement the "Improving Quality and Efficiency to Achieve Returns" action plan for the company in 2024.
Articles of Association of Sansure Biotech Inc.
Notice of the resolution of the third interim meeting of the second session of the Board of Supervisors of Sansure Biotech Inc. in 2024.
Announcement of Sansure Biotech Inc. on the Change of Registered Capital, Revision of Articles of Association and Business Registration
Announcement of Adjusting the Grant Price of Restricted Stock Incentive Plan for 2023 by Sansure Biotech Inc.
Legal Opinion of Qi Yuan Law Firm, regarding the adjustment of the grant price of restricted stock options and the achievement of the first vesting condition of Sansure Biotech Inc.'s 2023 Restricted Stock Incentive Plan.
Announcement of Sansure Biotech Inc.'s Restrictive Stock Incentive Plan for the first vesting period in 2023 that meets the ownership conditions.
Verification opinion of the first attribution list of the 2023 Restricted Stock Incentive Plan by the Supervisory Committee of Sansure Biotech Inc.
Announcement on the resolution of the fifth interim meeting of the second board of directors of Sansure Biotech Inc. in 2024.
Announcement of the Implementation of Share Repurchase and Cancellation as well as Share Changes by Sansure Biotech Inc.
Announcement of Sansure Biotech Inc. about obtaining government subsidies.
SanSure Biotech Inc.'s announcement on voluntarily disclosing the performance forecast for the first half of 2024.
Reply to the regulatory inquiry letter on information disclosure of Sansure Biotech Inc.'s 2023 annual report from Zhongshen Zhonghuan Accounting Firm (special general partnership)
Verification opinion on the reply to the regulatory inquiry letter on the disclosure of information in the 2023 annual report of sansure biotech inc. by western securities limited.
Announcement by Sansure Biotech Inc. regarding voluntary disclosure of the company's CE certification for related testing products in the European Union.
Announcement of Sansure Biotech Inc.'s reply to the regulatory inquiry letter regarding the disclosure of information in the 2023 annual report.
Announcement of Sansure Biotech Inc.'s voluntary disclosure of obtaining medical instrument registration certificate for related products.
Announcement of Sansure Biotech Inc.'s 2023 annual equity distribution implementation.
Legal opinion on the differentiated equity distribution of Sansure Biotech Inc. by Hunan Qiyuan Law Firm
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Shengxiang Biotechnology Co., Ltd.
No Data